Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Holding BIIB?
Track your performance easily
BIIB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$153.62 - $268.30
Previous Close$157.9
Volume1.70M
Average Volume (3M)1.32M
Market Cap
$23.01B
Enterprise Value$29.66B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.65B
Price to Earnings (P/E)14.3
Beta0.75
Next Earnings
Jan 30, 2025EPS Estimate
$3.42Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.07
Shares Outstanding145,719,340
10 Day Avg. Volume1,693,903
30 Day Avg. Volume1,321,528
Standard Deviation0.09
R-Squared0.00122
Alpha-0.00446
Financial Highlights & Ratios
Price to Book (P/B)1.39
Price to Sales (P/S)2.36
Price to Cash Flow (P/CF)6.10
P/FCF Ratio6.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit4.06
Enterprise Value/Ebitda9.49
Forecast
1Y Price Target
$247.59Price Target Upside56.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Biogen News
PremiumMarket News
SPY ETF Update, 11/22/2024 
PremiumMarket News
QQQ ETF Update, 11/21/2024 
PremiumMarket News
VOO ETF Update, 11/20/2024 
PremiumMarket News
SPY ETF Update, 11/19/2024 
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe EPS range was adjusted higher, suggesting a positive outlook on earnings.
Market GrowthEx-U.S. revenues swiftly grew to $28M, which is likely due to Eisai's strength in Asian markets like Japan, China, and South Korea, but could also indicate a refinement of the launch process.
Regulatory ApprovalBiogen partner Eisai's request for the EMA's CHMP to reexamine the MAA for lecanemab in amyloid-positive early Alzheimer's disease has paid off with a positive recommendation.
Bears Say
Financial PerformanceProduct Revenues came in approximately $80 million lower than expected.
Market CompetitionThe potential launch of LLY's Kisunla is expected to pose a competitive challenge to Leqembi.
Regulatory ChallengesThe EU CHMP recommended no approval for Leqembi stating the 'small' benefit on delaying cognitive decline does not outweigh the serious side effects, namely ARIA and especially in certain subgroups ApoE4 homozygous carriers who are higher risk.
---
Ownership Overview
0.14% Insiders
35.80% Mutual Funds
24.51% Other Institutional Investors
7.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $153.62 and its highest was $268.30 in the past 12 months.
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Jan 30, 2025 which is in 68 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 30, 2024. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.772 by $0.308.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is $3.42.
How many shares outstanding does Biogen have?
Biogen has 145,719,350 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $4.08 in its last earnings report, beating expectations of $3.772. Following the earnings report the stock price went down -1.248%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 3B.
---
Biogen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$247.59 (56.80% Upside)
$247.59 (56.80% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $88.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.71%
12-Months-Change
Fundamentals
Return on Equity
10.47%
Trailing 12-Months
Asset Growth
0.43%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q3 2024
0:00 / 0:00
---
BIIB Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
BIIB Stock 12 Month Forecast
Average Price Target
$247.59
▲(56.80% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
11/38 ratings generated profit
1 Year Average Return
-6.77%
reiterated a buy rating 24 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.95% of your transactions generating a profit, with an average return of -6.77% per trade.
---